Recent investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing significant results in addressing obesity and type 2 condition. Preclinical evidence suggest a novel process contributing https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/